Literature DB >> 19072461

Role of androgen excess on metabolic aberrations and cardiovascular risk in women with polycystic ovary syndrome.

Charikleia D Christakou1, Evanthia Diamanti-Kandarakis.   

Abstract

Polycystic ovary syndrome (PCOS) is associated with a clustering of metabolic and cardiovascular risk factors. Insulin resistance is implicated as the major player in the metabolic abnormalities and contributes to the increased cardiovascular risk associated with the syndrome. However, androgen excess appears to participate as an independent parameter, which further aggravates the cardiovascular and metabolic aberrations in affected women with PCOS. The resultant impact of hyperandrogenemia possibly acquires clinical significance for women's health in the context of PCOS, particularly since recent data support an increased incidence of coronary artery disease and of cardiovascular events directly related to androgen levels in women with the syndrome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19072461     DOI: 10.2217/17455057.4.6.583

Source DB:  PubMed          Journal:  Womens Health (Lond)        ISSN: 1745-5057


  29 in total

Review 1.  Androgens and Blood Pressure Control: Sex Differences and Mechanisms.

Authors:  Jane F Reckelhoff
Journal:  Mayo Clin Proc       Date:  2019-01-31       Impact factor: 7.616

Review 2.  Interplay between insulin resistance and estrogen deficiency as co- activators in carcinogenesis.

Authors:  Zsuzsanna Suba
Journal:  Pathol Oncol Res       Date:  2011-10-09       Impact factor: 3.201

3.  The effects of old, new and emerging medicines on metabolic aberrations in PCOS.

Authors:  Alexandra Bargiota; Evanthia Diamanti-Kandarakis
Journal:  Ther Adv Endocrinol Metab       Date:  2012-02       Impact factor: 3.565

4.  Aspects of Cardiometabolic Risk in Women with Polycystic Ovary Syndrome.

Authors:  Thomas S Paterakis; Evanthia Diamanti-Kandarakis
Journal:  Curr Obes Rep       Date:  2014-12

5.  Cardiovascular-renal and metabolic characterization of a rat model of polycystic ovary syndrome.

Authors:  Licy L Yanes; Damian G Romero; Mohaddetheh Moulana; Roberta Lima; Deborah D Davis; Huimin Zhang; Rachel Lockhart; Lorraine C Racusen; Jane F Reckelhoff
Journal:  Gend Med       Date:  2011-04

Review 6.  Polycystic ovary syndrome in the pediatric population.

Authors:  Andrew A Bremer
Journal:  Metab Syndr Relat Disord       Date:  2010-10       Impact factor: 1.894

7.  Cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes.

Authors:  Berna Dilbaz; Enis Ozkaya; Mehmet Cinar; Evrim Cakir; Serdar Dilbaz
Journal:  Endocrine       Date:  2011-03-10       Impact factor: 3.633

8.  Cardiovascular disease markers in women with polycystic ovary syndrome with emphasis on asymmetric dimethylarginine and homocysteine.

Authors:  Ahmed M Mohamadin; Fawzia A Habib; Abdulrahman A Al-Saggaf
Journal:  Ann Saudi Med       Date:  2010 Jul-Aug       Impact factor: 1.526

Review 9.  Reactive oxygen species: players in the cardiovascular effects of testosterone.

Authors:  Rita C Tostes; Fernando S Carneiro; Maria Helena C Carvalho; Jane F Reckelhoff
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-11-04       Impact factor: 3.619

Review 10.  Androgens for postmenopausal women's health?

Authors:  Tiziana Montalcini; Valeria Migliaccio; Yvelise Ferro; Carmine Gazzaruso; Arturo Pujia
Journal:  Endocrine       Date:  2012-05-12       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.